The relationship between interest rates and dividend stocks tends to follow a predictable pattern. When the Federal Reserve signals a shift toward monetary easing, investors often rotate toward stable, high-yielding equities that can provide both income and potential appreciation.Amgen (AMGN -0.02%) offers an intriguing test case for this dynamic heading into 2025. The biotech-giant's shares have slumped 3.37% in 2024, while the S&P 500 has surged 26.8% as of this writing, creating what might be a compellin ...

Amgen Inc. (NASDAQ:AMGN) Annual Evercore ISI HealthCONx Healthcare Conference December 4, 2024 10:00 AM ET Company Participants Peter Griffith - Executive Vice President and Chief Financial Officer James Bradner - Executive Vice President, Research and Development, and Chief Scientific Officer Susan Sweeney - Executive Vice President, Obesity and Related Conditions Justin Claeys - Vice President, Investor Relations Conference Call Participants Umer Raffat - Evercore ISI Umer Raffat Excellent. Hello, everyon ...

Amgen’s (AMGN) stock has declined 12.1% in the past month. Late last month, Amgen announced the much-awaited 52-week top-line data from a phase II study on MariTide, its GLP-1 therapy being developed for obesity and related conditions. The data showed that MariTide led to sustainable weight loss, robust and clinically meaningful improvements in cardiometabolic parameters and a strong reduction of average blood sugar levels.However, despite the encouraging data, Amgen’s stock has declined as the weight loss ...

The battle for the multibillion-dollar obesity market just got fiercer. Amgen Inc's AMGN new drug candidate, MariTide, reported promising results, helping patients shed around 20% of their body weight. But when up against the current titans — Eli Lilly And Co LLY and Novo Nordisk A/S NVO — "promising" may not cut it. Weight Loss: A Tough Market For Newcomers Eli Lilly and Novo Nordisk's drugs, Zepbound and Wegovy, aren't just treatments—they're juggernauts. Amgen's MariTide enters the fray with a unique ant ...

THOUSAND OAKS, Calif., Dec. 2, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at Citi's 2024 Global Healthcare Conference at 9:30 a.m. ET on Thursday, Dec. 5, 2024. Peter Griffith, executive vice president and chief financial officer at Amgen, Jay Bradner, executive vice president of Research and Development and chief scientific officer at Amgen, and Susan Sweeney, executive vice president of Obesity and Related Conditions at Amgen, will participate in a fireside chat at the conference. The webcast w ...

The biotech industry can be volatile even for relatively large companies. Amgen (AMGN 1.00%), one of the more prominent names in the game, just reminded us all of that fact. On Nov. 26, the company's shares dropped by as much as 12%. Unsurprisingly, the dip was due to clinical results the market filed under "not good enough." However, if Amgen can bounce back, now might be an excellent time for investors to scoop up its shares. Let's find out what the future holds for Amgen after its massive one-day drop. A ...

The market didn't appreciate Amgen's (AMGN 1.00%) latest clinical data update, with the biopharma's shares falling more than 12% at one point on Nov. 26 from the previous day's close, though they recovered to close just 4.7% down for the day. And, with shares of certain direct competitors, such as Eli Lilly (LLY 0.91%), rising, the prevailing assumption seems to be that one company's stumble is another's gain. But is the market's reaction appropriate, or is this a good opportunity to buy the dip? Let's take ...

THOUSAND OAKS, Calif., Nov. 29, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the 7th Annual Evercore HealthCONx Conference at 10:00 a.m. ET on Wednesday, Dec. 4, 2024. Peter Griffith, executive vice president and chief financial officer at Amgen, Jay Bradner, executive vice president of Research and Development and chief scientific officer at Amgen, and Susan Sweeney, executive vice president of Obesity and Related Conditions at Amgen, will participate in a fireside chat at the conference. The w ...

Shares of Amgen (AMGN 0.02%) are down by 6% in the last 30 days as I write this -- a larger-than-normal amount for a large pharma company's stock to fall, especially considering that the market rose nearly 3% in the same period. The clear culprit for the drop is, quite regrettably for shareholders, an unintentional disclosure of clinical trial information that the market found to be rather unappetizing.But does that change the investment thesis for buying the stock, or is it just a blip?This revelation is e ...

Key TakeawaysA new Amgen weight reduction drug, MariTide, has bred successful results after a 52-week study.Still, AMGN stock declined almost 5% on Tuesday as weight loss reduction was at the lower end of expectations.Register now to see our 7 Best Stocks for the Next 30 Days report - free today!Amgen (AMGN) announced the much-awaited 52-week top-line data from a phase II study on MariTide, its GLP-1 therapy being developed for obesity and related conditions.The data showed that MariTide led to sustainable ...